Shares of Conatus Pharmaceuticals Inc. (CNAT) were up more than 22% in extended trading on Tuesday, following positive 3-month data with Emricasan in initial stage of phase II liver cirrhosis clinical trial.
Forex – financial instrument.Forex news
Shares of Conatus Pharmaceuticals Inc. (CNAT) were up more than 22% in extended trading on Tuesday, following positive 3-month data with Emricasan in initial stage of phase II liver cirrhosis clinical trial.